PD-L1 prevalence in advanced urothelial carcinoma by demographic and clinical characteristics

被引：0
|
作者：
Powles, T. B. [1 ]
van der Heijden, M. S. [2 ]
Balar, A. V. [3 ]
O'Donnell, P. [4 ]
Massard, C. [5 ]
Walker, J. [6 ]
Gupta, A. [7 ]
Angra, N. [7 ]
Cairns, J. [8 ]
Turriziani, B. [6 ]
Rebelatto, M. C. [7 ]
Scott, M. [6 ]
Wildsmith, S. [6 ]
机构：
[1] Queen Mary Univ London, Barts Canc Inst, Ctr Expt Canc Med, London, England
[2] Netherlands Canc Inst, Div Med Oncol, Amsterdam, Netherlands
[3] NYU, Dept Med, Perlmutter Canc Ctr, Langone Med Ctr, 550 1St Ave, New York, NY 10016 USA
[4] Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA
[5] Gustave Roussy Canc Campus, DITEP, Villejuif, France
[6] AstraZeneca, Oncol R&D, Cambridge, England
[7] AstraZeneca, Oncol R&D, Gaithersburg, MD USA
[8] AstraZeneca, Stat, Cambridge, England
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.10.498
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
13P
引用
收藏
页码：S1421 / S1421
页数：1
相关论文
共 50 条
  • [21] PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis
    Ghate, Ketan
    Amir, Eitan
    Kuksis, Markus
    Hernandez-Barajas, David
    Rodriguez-Romo, Laura
    Booth, Christopher M.
    Vera-Badillo, Francisco E.
    CANCER TREATMENT REVIEWS, 2019, 76 : 51 - 56
  • [22] PREVALENCE OF PD-L1 AND OTHER SELECTED BIOMARKERS IN ADVANCED UROTHELIAL AND ESOPHAGEAL CARCINOMA AND ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA IN TWO REFERENCE INSTITUTIONS OF COLOMBIA
    Hinestrosa, F.
    Urrego-Reyes, J.
    Beltran, C.
    Gaitan Hemelberg, M. A.
    Escobar, J.
    Rodriguez, J.
    Cardona, A. F.
    VALUE IN HEALTH, 2022, 25 (12) : S482 - S482
  • [23] Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma
    Spassova, Ivelina
    Ugurel, Selma
    Kubat, Linda
    Zimmer, Lisa
    Terheyden, Patrick
    Mohr, Annalena
    Andtback, Hannah Bjorn
    Villabona, Lisa
    Leiter, Ulrike
    Eigentler, Thomas
    Loquai, Carmen
    Hassel, Jessica C.
    Gambichler, Thilo
    Haferkamp, Sebastian
    Mohr, Peter
    Pfoehler, Claudia
    Heinzerling, Lucie
    Gutzmer, Ralf
    Utikal, Jochen S.
    Horny, Kai
    Schildhaus, Hans-Ulrich
    Habermann, Daniel
    Hoffmann, Daniel
    Schadendorf, Dirk
    Becker, Juergen Christian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)
  • [24] PD-L1 Immunoreactivity and Immune Pathway Markers in Urothelial Carcinoma
    McKnight, Tristan F.
    Tacha, David
    Shabaik, Ahmed
    Hansel, Donna
    LABORATORY INVESTIGATION, 2018, 98 : 367 - 367
  • [25] A study of PD-L1 diagnostic assay concordance in urothelial carcinoma
    Zajac, Magdalena
    Scott, Marietta
    Ratcliffe, Marianne
    Sharpe, Alan
    Scorer, Paul W.
    Barker, Craig
    Al-Masri, Hytham
    Rebelatto, Marlon
    Walker, Jill
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [26] PD-L1 and IDO Expression in Upper Tract Urothelial Carcinoma
    Cathro, Helen
    Ju, Jennifer
    Davick, Jonathan
    Gru, Alejandro A.
    Culp, Stephen
    MODERN PATHOLOGY, 2019, 32
  • [27] PD-L1 and IDO Expression in Upper Tract Urothelial Carcinoma
    Cathro, Helen
    Ju, Jennifer
    Davick, Jonathan
    Gru, Alejandro A.
    Culp, Stephen
    LABORATORY INVESTIGATION, 2019, 99
  • [28] PD-L1 Immunoreactivity and Immune Pathway Markers in Urothelial Carcinoma
    McKnight, Tristan F.
    Tacha, David
    Shabaik, Ahmed
    Hansel, Donna
    MODERN PATHOLOGY, 2018, 31 : 367 - 367
  • [29] Improving the Cost Efficiency of PD-1/PD-L1 Inhibitors for Advanced Urothelial Carcinoma: A Major Role for Precision Medicine?
    Sonpavde, Guru
    Dranitsaris, George
    Necchi, Andrea
    EUROPEAN UROLOGY, 2018, 74 (01) : 63 - 65
  • [30] First-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC).
    Agarwal, Archana
    Pond, Gregory Russell
    Drakaki, Alexandra
    Lee, Jae-Lyun
    Bilen, Mehmet Asim
    Di Lorenzo, Giuseppe
    Grivas, Petros
    Ornstein, Moshe Chaim
    Barata, Pedro C.
    Gupta, Shilpa
    Hussain, Syed A.
    Curran, Catherine
    Garcia, Jorge A.
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
12345